SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondylarthropathies. Rheum Dis Clin North Am 1995; 21: 11728.
  • 2
    Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J. Biologic therapies in the spondyloarthritis: new opportunities, new challenges. Curr Opin Rheumatol 2003; 15: 394407.
  • 3
    Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicenter trial. Lancet 2002; 359: 118793.
  • 4
    Braun J, Sieper J, Breban M, Zink A, Alten R, Golder W, et al. Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience. Ann Rheum Dis 2002; 61 Suppl 3: 5160.
  • 5
    Braun J, Sieper J. Building consensus of nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18–19 January 2002. Ann Rheum Dis 2002; 61 Suppl 3: 617.
  • 6
    Dougados M. Diagnosis and monitoring of spondylarthropathy. Compr Ther 1990; 16: 526.
  • 7
    Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002; 61 Suppl 3: 4050.
  • 8
    Miceli-Richard C, Dougados M. NSAIDS in ankylosing spondylitis. Clin Exp Rheumatol 2002; 20 Suppl 28: S656.
  • 9
    Leung AT, Malmstrom K, Gallacher AE, Sarembock B, Poor G, Beaulieu A, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002; 18: 4958.
  • 10
    Zacher J, Feldman D, Gerli R, Scott D, Hou SM, Uebelhart D, et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin 2003; 19: 72536.
  • 11
    Birbara CA, Puopolo AD, Munoz DR, Sheldon EA, Mangione A, Bohidar NR, et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability: a randomized, placebo-controlled, 3-month trial. J Pain 2003; 4: 30715.
  • 12
    Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Pract 2002; 3: 10.
  • 13
    Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002; 29: 162330.
  • 14
    Malmstrom K, Kotey P, Cichanowitz N, Daniels S, Desjardins PJ. Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial. Gynecol Obstet Invest 2003; 56: 659.
  • 15
    Malmstrom K, Kotey P, Coughlin H, Desjardins PJ. A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model. Clin J Pain 2004; 20: 14755.
  • 16
    Schumacher HR Jr, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, et al. Randomised double-blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002; 324: 148892.
  • 17
    Hunt RH, Harper S, Callegari P, Yu C, Quan H, Evans J, et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003; 17: 20110.
  • 18
    Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98: 172533.
    Direct Link:
  • 19
    Curtis S, Bolognese J, Lee M, Watson DJ, Harper S. GI-related treatment discontinuations with etoricoxib compared with nonselective cyclooxygenase inhibitors (NSAIDs) and placebo [abstract]. Ann Rheum Dis 2002; 61 Suppl 1: 187.
  • 20
    Curtis S, Bolognese J, Lee M, Watson DJ, Harper S. Usage of concomitant gastroprotective agents with etoricoxib, nonselective cyclooxygenase inhibitors (NSAIDs), and placebo [abstract]. Ann Rheum Dis 2002; 61 Suppl 1: 207.
  • 21
    Harper S, Bolognese J, Lee M, Watson DJ, Curtis S. Fewer GI-related treatment discontinuations with etoricoxib compared with nonselective cyclooxygenase inhibitors (NSAIDs) [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S317.
  • 22
    Calin A, Elswood J. A prospective nationwide cross-sectional study of NSAID usage in 1331 patients with ankylosing spondylitis. J Rheumatol 1990; 17: 8013.
  • 23
    Wasner C, Britton MC, Kraines RG, Kaye RL, Bobrove AM, Fries JF. Nonsteroidal anti-inflammatory agents in rhematoid arthritis and ankylosing spondylitis. JAMA 1981; 246: 216872.
  • 24
    Burry HC, Siebers R. A comparison of flurbiprofen with naproxen in ankylosing spondylitis. N Z Med J 1980; 92: 30911.
  • 25
    Hill HF, Hill AG. Ankylosing spondylitis: open long-term and double-blind crossover studies with naproxen. J Clin Pharmacol 1975; 15: 35562.
  • 26
    SweetmanSC, editor. Naproxen. In: Martindale: the complete drug reference. 33rd ed. London: Pharmaceutical Press; 2002. p. 602.
  • 27
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 3618.
  • 28
    Calin A, Garrett S, Whitelock H, Kennedy LG, Ohea J, Mallorie-P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 22815.
  • 29
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 228691.
  • 30
    Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 187686.
  • 31
    Dougados M, Gueguen A, Nakache JP, Velicitat P, Veys EM, Zeidler H, et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) 1999; 38: 23544.
  • 32
    Chow SC, Liu JP. Design and analysis of clinical trials: concepts and methodologies. 2nd ed. New York: John Wiley & Sons; 2003.
  • 33
    Curtis SP, Mukhopadhyay S, Ramey D, Reicin A. Cardiovascular safety summary associated with the etoricoxib development program [abstract]. Arthritis Rheum 2003; 48 Suppl 9: S616.
  • 34
    Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005. E-pub ahead of print.
  • 35
    Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005. E-pub ahead of print.